Sei Investments Co. Sells 69,599 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Sei Investments Co. cut its position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 48.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,242 shares of the company’s stock after selling 69,599 shares during the quarter. Sei Investments Co.’s holdings in Kodiak Sciences were worth $739,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Peapod Lane Capital LLC purchased a new stake in Kodiak Sciences in the fourth quarter worth about $1,660,000. FMR LLC raised its position in shares of Kodiak Sciences by 26.4% in the 3rd quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after acquiring an additional 41,987 shares in the last quarter. Barclays PLC lifted its stake in shares of Kodiak Sciences by 65.5% in the 3rd quarter. Barclays PLC now owns 79,658 shares of the company’s stock valued at $208,000 after purchasing an additional 31,527 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Kodiak Sciences by 220.9% during the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock valued at $117,000 after purchasing an additional 30,735 shares in the last quarter. Finally, AlphaQuest LLC bought a new stake in shares of Kodiak Sciences during the fourth quarter valued at approximately $256,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $3.00 target price on shares of Kodiak Sciences in a research note on Monday, March 31st.

Kodiak Sciences Stock Performance

Shares of Kodiak Sciences stock opened at $2.06 on Wednesday. Kodiak Sciences Inc. has a fifty-two week low of $2.01 and a fifty-two week high of $11.60. The company has a market capitalization of $108.66 million, a P/E ratio of -0.56 and a beta of 2.40. The company has a fifty day moving average of $4.02 and a 200 day moving average of $5.41.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.06. Analysts forecast that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.